Gene fusions result from either structural chromosomal rearrangement or aberrations caused by splicing or transcriptional readthrough. The precise and distinctive presence of fusion genes in neoplastic tissues and their involvement in multiple pathways central to cancer development, growth and survival make them promising targets for personalized therapy. In genitourinary malignancies, rearrangements involving the E26 transformation-specific family of transcription factors have emerged as very frequent alterations in prostate cancer, especially the TMPRSS2–ERG fusion. In renal malignancies, Xp11 and t(6;11) translocations are hallmarks of a distinct pathological group of tumours described as microphthalmia-associated transcription factor family translocation-associated renal cell carcinomas. Novel druggable fusion events have been recognized in genitourinary malignancies, leading to the activation of several clinical trials. For instance, ALK-rearranged renal cell carcinomas have shown responses to alectinib and crizotinib. Erdafitinib has been tested for the treatment of FGFR-rearranged bladder cancer. Other anti-fibroblast growth factor receptor 3 (FGFR3) compounds are showing promising results in the treatment of bladder cancer, including infigratinib and pemigatinib, and all are currently in clinical trials.
Gene fusions and rearrangements represent potentially targetable alterations in several different malignancies, including genitourinary tumours.
TMPRSS2–ERG fusion is present in 40–50% of prostate cancers and has a critical role in tumorigenesis and progression by disrupting the androgen receptor differentiation of prostate cells.
FGFR3–TACC fusion in urothelial carcinoma has proven to be an effective target of anti-fibroblast growth factor receptor (FGFR) compounds, such as erdafitinib, in phase II clinical trials.
Xp11 and t(6;11) translocations and their related fusion events represent the hallmark aberrations of the microphthalmia-associated transcription factor family translocated renal cell carcinomas.
Application of standardized and easy-to-use classification frameworks (such as ESMO Scale for Clinical Actionability (ESCAT) and OncoKB) to the multitude of gene fusions identifiable by next-generation sequencing is necessary to foster the translation of gene fusion research into effective clinical practice.
Results from site-agnostic, biomarker-guided trials including strong translational investigations would help move forwards our understanding of the pathobiology and druggability of rare, low-prevalence gene fusions.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mertens, F., Johansson, B., Fioretos, T. & Mitelman, F. The emerging complexity of gene fusions in cancer. Nat. Rev. Cancer 15, 371–381 (2015).
Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233–245 (2007).
Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45, D777–D783 (2017).
Loriot, Y. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 381, 338–348 (2019).
Teles Alves, I. et al. Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line. Hum. Genet. 132, 709–713 (2013).
Nakanishi, Y. et al. Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1. Mol. Cancer Ther. 14, 704–712 (2015).
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
Williams, S. V., Hurst, C. D. & Knowles, M. A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795–803 (2013).
Hood, F. E. & Royle, S. J. Pulling it together: the mitotic function of TACC3. Bioarchitecture 1, 105–109 (2011).
Schneider, L. et al. The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival. J. Biol. Chem. 282, 29273–29283 (2007).
Parker, B. C. et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Invest. 123, 855–865 (2013).
Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16, 793–798 (2010).
Zhang, Y. et al. Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Discov. 2, 598–607 (2012).
Abeshouse, A. et al. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).
Tomlins, S. A. et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 56, 275–286 (2009).
Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595–599 (2007).
Yu, J. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443–454 (2010).
Feng, F. Y., Brenner, J. C., Hussain, M. & Chinnaiyan, A. M. Molecular pathways: targeting ETS gene fusions in cancer. Clin. Cancer Res. 20, 4442–4448 (2014).
Zong, Y. et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl Acad. Sci. USA 106, 12465–12470 (2009).
Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619–624 (2009).
Mani, R. S. et al. Inflammation-induced oxidative stress mediates gene fusion formation in prostate cancer. Cell Rep. 17, 2620–2631 (2016).
Arora, R. et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100, 2362–2366 (2004).
Brastianos, H. C. et al. Determining the impact of spatial heterogeneity on genomic prognostic biomarkers for localized prostate cancer. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2020.06.005 (2020).
Fontugne, J. et al. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Mod. Pathol. 29, 157–165 (2016).
Mehra, R. et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 68, 3584–3590 (2008).
Helgeson, B. E. et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73–80 (2008).
Han, B. et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 68, 7629–7637 (2008).
Luo, J.-H. et al. Discovery and classification of fusion transcripts in prostate cancer and normal prostate tissue. Am. J. Pathol. 185, 1834–1845 (2015).
Tomlins, S. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396–3400 (2006).
Boormans, J. L. et al. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer. Eur. Urol. 57, 830–835 (2010).
Karnes, R. J. et al. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res. 70, 8994–9002 (2010).
Leinonen, K. A. et al. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin. Cancer Res. 16, 2845–2851 (2010).
Attard, G. et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912–2918 (2009).
Danila, D. C. et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol. 60, 897–904 (2011).
Pilié, P. G., Tang, C., Mills, G. B. & Yap, T. A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16, 81–104 (2019).
Tripathi, A., McFarland, T. & Agarwal, N. PARP inhibitors in prostate cancer: a promise delivered. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2020.08.006 (2020).
Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664–678 (2011).
Brenner, J. C. et al. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res. 72, 1608–1613 (2012).
Antonarakis, E. S., Gomella, L. G. & Petrylak, D. P. When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2020.07.005 (2020).
Hussain, M. et al. Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data [abstract]. J. Clin. Oncol. 35 (Suppl. 15), 5001 (2017).
Sandhu, S. K. et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 14, 882–892 (2013).
Conteduca, V. et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann. Oncol. 28, 1508–1516 (2017).
Alshalalfa, M. et al. Transcriptomic and clinical characterization of neuropeptide Y expression in localized and metastatic prostate cancer: identification of novel prostate cancer subtype with clinical implications. Eur. Urol. Oncol. 2, 405–412 (2019).
Shinde, D. et al. Transcriptional reprogramming and inhibition of tumor-propagating stem-like cells by EC-8042 in ERG-positive prostate cancer. Eur. Urol. Oncol. 2, 415–424 (2019).
Ross, J. S. et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int. J. Cancer 138, 881–890 (2016).
Beltran, H. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920–926 (2013).
Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269–273 (2011).
Annala, M. et al. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. Oncotarget 6, 6235–6250 (2015).
Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).
Hakenberg, O. W. et al. Penile Cancer. in EAU Guidelines. Edn presented at the EAU Annual Congress Copenhagen 2018 (EAU Guidelines Office, 2018).
Aydin, A. M. et al. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat. Rev. Urol. https://doi.org/10.1038/s41585-020-0359-z (2020).
Barocas, D. A. & Chang, S. S. Penile cancer: clinical presentation, diagnosis, and staging. Urol. Clin. North Am. 37, 343–352 (2010).
Couturier, J., Sastre-Garau, X., Schneider-Maunoury, S., Labib, A. & Orth, G. Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. J. Virol. 65, 4534–4538 (1991).
Lam, K. Y. & Chan, K. W. Molecular pathology and clinicopathologic features of penile tumors: with special reference to analyses of p21 and p53 expression and unusual histologic features. Arch. Pathol. Lab. Med. 123, 895–904 (1999).
Ferreux, E. et al. Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J. Pathol. 201, 109–118 (2003).
Jacob, J. M. et al. Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J. Urol. 201, 541–548 (2019).
Zhou, Q. et al. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Cell Death Dis. 9, 384 (2018).
Albers, P. et al. in EAU Guidelines. Edn Presented at the EAU Annual Congress Copenhagen 2018 (EAU Guidelines Office, 2018).
Litchfield, K. et al. Large-scale sequencing of testicular germ cell tumour (TGCT) cases excludes major TGCT predisposition gene. Eur. Urol. 73, 828–831 (2018).
Hoff, A. M. et al. Identification of novel fusion genes in testicular germ cell tumors. Cancer Res. 76, 108–116 (2016).
Necchi, A. et al. Genomic features for therapeutic insights of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors and comparison with gonadal counterpart. Oncologist 24, e142–e145 (2019).
Necchi, A. et al. Genomic characterization of testicular germ cell tumors relapsing after chemotherapy. Eur. Urol. Focus 6, 122–130 (2020).
Necchi, A. et al. Genomic features of metastatic testicular sex cord stromal tumors [abstract]. J. Clin. Oncol. 37 (Suppl. 7), 532 (2019).
Gao, Q. et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 23, 227–238.e3 (2018).
Argani, P. et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am. J. Pathol. 159, 179–192 (2001).
Argani, P. et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am. J. Pathol. 158, 2089–2096 (2001).
Kauffman, E. C. et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat. Rev. Urol. 11, 465–475 (2014).
Moch, H. M., Humphrey, P., Ulbright, T. & Reuter, V. WHO Classification of Tumours of the Urinary System and Male Genital Organs (WHO, 2016).
Pastore, G. et al. Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 42, 2103–2114 (2006).
Selle, B. et al. Population-based study of renal cell carcinoma in children in Germany, 1980-2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer 107, 2906–2914 (2006).
Argani, P. et al. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am. J. Surg. Pathol. 33, 609–619 (2009).
Argani, P. et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am. J. Surg. Pathol. 34, 1395–1406 (2010).
Argani, P. et al. TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers. Am. J. Surg. Pathol. 40, 723–737 (2016).
Argani, P. et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am. J. Surg. Pathol. 26, 1553–1566 (2002).
Davis, I. J. et al. Cloning of an alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc. Natl Acad. Sci. USA 100, 6051–6056 (2003).
Skala, S. L. et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod. Pathol. 31, 179–197 (2018).
Argani, P. et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am. J. Surgical Pathol. 40, 1484–1495 (2016).
Tsuda, M. et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 67, 919–929 (2007).
Wagner, A. J. et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 118, 5894–5902 (2012).
Turajlic, S. & Swanton, C. TRACERx renal: tracking renal cancer evolution through therapy. Nat. Rev. Urol. 14, 575–576 (2017).
Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell 173, 611–623.e17 (2018).
Sukov, W. R. et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod. Pathol. 25, 1516–1525 (2012).
Butrynski, J. E. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727–1733 (2010).
Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
Smith, N. E. et al. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? Am. J. Surg. Pathol. 38, 858–863 (2014).
Sugawara, E. et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 118, 4427–4436 (2012).
Kusano, H. et al. Two cases of renal cell carcinoma harboring a novel STRN-ALK fusion gene. Am. J. Surg. Pathol. 40, 761–769 (2016).
Pal, S. K. et al. Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur. Urol. 74, 124–128 (2018).
Schöffski, P. et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur. J. Cancer 87, 147–163 (2017).
Pal, S. K. et al. A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500 [abstract]. J. Clin. Oncol. 35 (Suppl. 15), TPS4599 (2017).
Durinck, S. et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat. Genet. 47, 13–21 (2015).
Haq, R. & Fisher, D. E. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J. Clin. Oncol. 29, 3474–3482 (2011).
Dynek, J. N. et al. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 68, 3124–3132 (2008).
Okamura, R. et al. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis. Oncol. https://doi.org/10.1200/PO.18.00183 (2018).
Jin, W. et al. Cellular transformation and activation of the phosphoinositide-3-kinase-akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Res. 67, 3192–3200 (2007).
Cocco, E., Scaltriti, M. & Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15, 731–747 (2018).
Drilon, A. et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400–409 (2017).
Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Eng. J. Med. 378, 731–739 (2018).
Tony, I., Marco, G., Bahleda, R. & Yohann, L. Clinical development of FGFR3 inhibitors for the treatment of urothelial cancer. Bladder Cancer 5, 87–12 (2019).
di Martino, E., Tomlinson, D. C. & Knowles, M. A. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv. Urol. 2012, 429213 (2012).
Helsten, T. et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259–267 (2016).
Necchi, A. et al. Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma. Eur. Urol. Focus https://doi.org/10.1016/j.euf.2020.08.001 (2020).
Blaszyk, H. et al. Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis. Mod. Pathol. 15, 790–797 (2002).
Hartmann, A. et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res. 62, 6796–6802 (2002).
Ross, J. S. et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod. Pathol. 27, 271–280 (2014).
Pal, S. K. et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 8, 812–821 (2018).
Necchi, A. et al. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA) [abstract 900P]. Ann. Oncol. 29 (Suppl. 8), viii319–viii320 (2018).
Necchi, A. et al. Fierce-21: phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC) [abstract]. J. Clin. Oncol. 37 (Suppl. 7), 409 (2019).
Loriot, Y. et al. Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study [abstract 920TiP]. Ann. Oncol. 29 (Suppl. 8), viii327–viii328 (2018).
Sternberg, C. N. et al. Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression [abstract 930TiP]. Ann. Oncol. 29 (Suppl. 8), viii331 (2018).
Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 174, 1033 (2018).
McConkey, D. J. et al. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol. Oncol. Clin. North Am. 29, 377–394 (2015).
Siefker-Radtke, A. & Curti, B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat. Rev. Urol. 15, 112–124 (2018).
Li, Q., Bagrodia, A., Cha, E. K. & Coleman, J. A. Prognostic genetic signatures in upper tract urothelial carcinoma. Curr. Urol. Rep. 17, 12 (2016).
Haugsten, E. M., Wiedlocha, A., Olsnes, S. & Wesche, J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol. Cancer Res. 8, 1439–1452 (2010).
Necchi, A. et al. Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2020.04.005 (2020).
Necchi, A. et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur. Urol. 77, 701–710 (2020).
Siefker-Radtke, A. O. et al. Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC) [abstract]. J. Clin. Oncol. 36 (Suppl. 6), 450 (2018).
Joerger, M. et al. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 4513 (2018).
Galsky, M. D. et al. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC) [abstract]. J. Clin. Oncol. 36 (Suppl. 6), 511 (2018).
Bandini, M. et al. Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djaa076 (2020).
Grivas, P. et al. Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2019.02.004 (2019).
Yates, L. R. et al. The European Society for Medical Oncology (ESMO) precision medicine glossary. Ann. Oncol. 29, 30–35 (2018).
Nelson, K. N. et al. Oncogenic gene fusion FGFR3-TACC3 is regulated by tyrosine phosphorylation. Mol. Cancer Res. 14, 458–469 (2016).
Vandekerkhove, G. et al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin. Cancer Res. 23, 6487–6497 (2017).
Tomlins, S. A. et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur. Urol. 70, 45–53 (2016).
Park, K. et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J. Clin. Oncol. 32, 206–211 (2014).
Sanda, M. G. et al. Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. JAMA Oncol. 3, 1085–1093 (2017).
Sukov, W. R. et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am. J. Surg. Pathol. 36, 663–670 (2012).
Ellis, C. L. et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod. Pathol. 27, 875–886 (2014).
Sboner, A. et al. FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol. 11, R104 (2010).
Kim, D. & Salzberg, S. L. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 12, R72 (2011).
McPherson, A. et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLOS Comput. Biol. 7, e1001138 (2011).
Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895–1902 (2018).
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. https://doi.org/10.1200/PO.17.00011 (2017).
Sleijfer, S., Bogaerts, J. & Siu, L. L. Designing transformative clinical trials in the cancer genome era. J. Clin. Oncol. 31, 1834–1841 (2013).
Lemery, S., Keegan, P. & Pazdur, R. First, F. D. A. Approval agnostic of cancer site – when a biomarker defines the indication. N. Engl. J. Med. 377, 1409–1412 (2017).
US Food and Drug Administration. Highlights of prescribing Information: VITRAKVI® (larotrectinib) capsules, for oral use. VITRAKVI® (larotrectinib) oral solution. FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf (2018).
Mehra, R. et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 67, 7991–7995 (2007).
Siefker-Radtke, A. O. et al. FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis [abstract]. J. Clin. Oncol. 37 (Suppl. 15), 4511 (2019).
Drilon, A. et al. STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions [abstract]. Cancer Res. 77 (Suppl. 13), CT060 (2017).
Powles, T. et al. BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer [abstract]. J. Clin. Oncol. 34 (Suppl. 15), TPS4577 (2016).
Voss, M. H. et al. First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors [abstract]. J. Clin. Oncol. 32 (Suppl. 15), TPS2629 (2014).
Joerger, M. et al. Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression [abstract]. J. Clin. Oncol. 36 (Suppl. 6), 494 (2018).
Rosenberg, J. et al. Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression [abstract 925TiP]. Ann. Oncol. 29 (Suppl. 8), viii329 (2018).
The authors declare no competing interests.
About this article
Cite this article
Pederzoli, F., Bandini, M., Marandino, L. et al. Targetable gene fusions and aberrations in genitourinary oncology. Nat Rev Urol (2020). https://doi.org/10.1038/s41585-020-00379-4